U.S. FDA approves biosimilar version of cancer drug Avastin

Thursday, 14 September 2017  (6 days ago)
(Reuters) - The U.S. Food and Drug Administration said on Thursday it has approved Amgen Inc's biosimilar version of Roche Holding AG's cancer drug Avastin.

Related Videos

TODAY’S TMJ4 -   ▶  01:09


GOBankingRates -   ▶  01:44

Recent related news

In 2016, Roche sold $3 billion worth of its blockbuster biotechnology drug Avastin. Last week, the Food and Drug Administration approved what’s expected to be...
18 hours ago • SFGate
SAN FRANCISCO--(BUSINESS WIRE)--Jaguar Health, Inc. (NASDAQ:JAGX) (Jaguar), a natural-products pharmaceuticals company focused on developing and commercializing...
3 hours ago • Business Wire
This is a bull market, and some biotech stocks are the real raging bulls—especially when massive drug pipelines are at stake, and landmark FDA approvals shake...
1 week ago • OilPrice.com
STRASBOURG, France--(BUSINESS WIRE)--#HBV--Regulatory News: Transgene (Paris:TNG), a biotech company that designs and develops viral-based immunotherapies, today...
1 week ago • Business Wire
Cycle Pharmaceuticals Ltd ("Cycle") is pleased to announce that it has received approval from the U.S. Food and Drug Administration ("FDA") of its Abbreviated...
1 day ago • FinanzNachrichten.de
YARDLEY, Pa.--(BUSINESS WIRE)--Optinose, an ENT / Allergy specialty pharmaceutical company, announced today that the U.S. Food & Drug Administration (FDA)...
2 days ago • Business Wire

You might like